Overview

A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography

Status:
Withdrawn

Trial end date:
2018-12-01

Target enrollment:
0

Participant gender:
All

Summary

Patients with an allergy to iodine based intravenous contrast cannot undergo a CT scan with contrast, unless they are premedicated. Premedication can result in a delay in diagnosis, that can be significant with acute conditions such as Pulmonary embolism. The investigators are evaluating the use of Gadolinium as an alternative contrast agent in CT. Gadolinium has been used extensively in MRI exams but the dose that is used is not sufficient to provide good enhancement on CT. Dual Energy CT is a new technology that has better sensitivity to lower doses of intravenous contrast and the investigators aim to study its effectiveness in improving the enhancement with Gadolinium. The investigators will compare enhancement of Iodine with enhancement of Gadolinium during Dual Energy CT, to assess the possibility that Gadolinium could be used as an alternative for patients who are suspected of having Pulmonary embolism. They will recruit up to 50 patients who are having a routine Chest CT during treatment for a malignancy and administer Gadolinium contrast and Iodine contrast during a chest CT exam. The enhancement with the two agents can be compared.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Massachusetts General Hospital

Criteria

Inclusion Criteria:

- patients required to undergo a clinically indicated CT examination

Exclusion Criteria:

- subject less than 56 yrs of age

- pregnant women

- Non English speaking

- Abnormal Renal function

- Allergy to Gadolinium